Conferences - Results from #200

AUA 2022: BCG Unresponsive Bladder Cancer May 16, 2022

AUA 2022: Timing of Radical Cystectomy in BCG Unresponsive Disease May 16, 2022

AUA 2022: Case-Based Debate: Do I Need to do Repeat TUR for All High Grade NMIBC Patients? Con May 16, 2022

AUA 2022: PSMA is here in the U.S. - Now What? May 16, 2022

AUA 2022: The Impact of Older Age on the Oncological Outcomes for High-Risk Metastatic Hormone-Sensitive Prostate Cancer Treated with Upfront Intensive Therapy May 16, 2022

AUA 2022: Prognostic Significance of Risk Stratification in CHAARTED and LATITUDE Studies Among Japanese Men with CRPC May 16, 2022

AUA 2022: Which Patients with cN1 Disease at PET/CT Are Affected by Systemic Disease? Implications for Tailored Treatment Approaches Based on a Large Multi-Institutional Series May 16, 2022

AUA 2022: When is Neoadjuvant Androgen Deprivation Therapy Beneficial for Highly Aggressive Prostate Cancer Candidates to Radical Prostatectomy? Implications for Multi-modal Tailored Approaches and Trials Design May 16, 2022

AUA 2022: The Impact of Older Age on the Oncological Outcomes for High-Risk mHSPC Treated with Upfront Intensive Therapy May 16, 2022

AUA 2022: State-of-the-Art Lecture: IBCG Master Class on TURBT May 16, 2022

AUA 2022: State-of-the-Art Lecture Discussant May 16, 2022

Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting May 16, 2022

Lantheus Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting May 16, 2022

AUA 2022: 18F-DCFPyL PSMA PET Imaging Improves Detection of Nodal Metastases in Comparison to Conventional Imaging in Patients with Locally Advanced or Oligometastatic Prostate Cancer May 16, 2022

AUA 2022: Oncological Outcomes in Patients With Recurrent Prostate Cancer Staged With PSMA PET/CT: Results From 3 European Tertiary Centers May 16, 2022

AUA 2022: Chemoablation as Primary Treatment: Transforming the Paradigm for Low Grade UTUC with JELMYTO® May 16, 2022

AUA 2022: Impact of 68Ga-PSMA PET/CT and Metastasis-Directed Therapy on Clinical Recurrence in Patients with Biochemical Recurrence after Radical Prostatectomy. Results from a Single Center Series May 15, 2022

AUA 2022: Development of a Novel Nomogram to Identify Candidates for Extended Pelvic Lymph-Node Dissection in Prostate Cancer using MRI and PSMA PET May 15, 2022

AUA 2022: Risk of Metabolic and Cardiovascular Adverse Events with Abiraterone or Enzalutamide Among Men with Advanced Prostate Cancer May 15, 2022

AUA 2022: When Node-Positive Prostate Cancer Should Be Considered A Systemic Disease? Assessing The Prognostic Role Of Preoperative 68Ga-PSMA PET/CT Results In Patients With Lymph Node Invasion At Final Pathology May 15, 2022

Page 11 of 472

email news signup